Synergistic effect of vascular endothelial growth factor and granulocyte colony-stimulating factor double gene therapy in mouse limb ischemia

Journal of Gene Medicine

Volumn 12, Issue 3, 2010, Pages 310-319

  Sacramento, Chester Bittencourt ^a   Da Silva, Flavia Helena ^a,b   Nardi, Nance Beyer ^b   Yasumura, Eduardo Gallatti ^a   Baptista Silva, Jośe Carlos Costa ^a   Beutel, Abram ^a   De Campos, Ruy Ribeiro ^a   De Moraes, Jane Zveiter ^a   Silva Jr , Hamilton ^c   Samoto, Vivian Yochiko ^a,d   Borojevic, Radovan ^d,e   Han, Sang Won ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Excellion Biomedical Services   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

Angiogenesis; Electroporation; GCSF; Limb ischemia; VEGF

Indexed keywords

BETA GALACTOSIDASE; GRANULOCYTE COLONY STIMULATING FACTOR; PLASMID VECTOR; STEM CELL ANTIGEN 1; VASCULOTROPIN;

ANGIOGENIC GENE THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG POTENTIATION; ELECTROPORATION; GASTROCNEMIUS MUSCLE; LIMB ISCHEMIA; MALE; MOUSE; MUSCLE FORCE; MUSCLE MASS; MUSCLE NECROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ANIMALS; EXTREMITIES; GENE THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; ISCHEMIA; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; REGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS;

EID: 77349121629     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1434     Document Type: Article

References (48)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45(Suppl S): S5-S67.
2. Hammond HK,McKirnan MD. Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials. Cardiovasc Res 2001; 49: 561-567.
3. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009; 105: 724-736.
4. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007; 15: 1233-1247.
5. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-581.
6. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
7. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343.
8. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
9. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
10. Bauters C, Asahara T, Zheng LP, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314-324.
11. Becit N, Ceviz M, Kocak H, et al. The effect of vascular endothelial growth factor on angiogenesis: an experimental study. Eur J Vasc Endovasc Surg 2001; 22: 310-316.
12. Takeshita S, Rossow ST, Kearney M, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995; 147: 1649-1660.
13. Takeshita S, Weir L, Chen D, et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227: 628-635.
14. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limbmodel. J Clin Invest 1994; 93: 662-670.
15. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.
16. van Weel V, Deckers MM, Grimbergen JM, et al. Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res 2004; 95: 58-66.
17. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
18. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973.
19. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374.
20. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114: 85-92.
21. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006; 17: 683-691.
22. Mäkinen K, Manninen H,Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
23. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938.
24. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
25. Avalos BR, Gasson JC, Hedvat C, et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 1990; 75: 851-857.
26. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 2005; 45: 321-325.
27. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-196.
28. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104: 65-72.
29. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-1297.
30. Iwanaga K, Takano H, Ohtsuka M, et al. Effects of G-CSF on cardiac remodeling after acute myocardial infarction in swine. Biochem Biophys Res Commun 2004; 325: 1353-1359.
31. OrlicD, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98: 10344-10349.
32. Zohlnhofer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003-1010.
33. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751-756.
34. Valgimigli M, Rigolin GM, Cittanti C, et al. Use of granulocytecolony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005; 26: 1838-1845.
35. Ince H, Petzsch M, Kleine HD, et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005; 112: 3097-3106.
36. Takagi Y, Omura T, Yoshiyama M, et al. Granulocyte-colony stimulating factor augments neovascularization induced by bone marrow transplantation in rat hindlimb ischemia. J Pharmacol Sci 2005; 99: 45-51.
37. Jeon O, Song SJ, Bhang SH, Choi CY, Kim MJ, Kim BS. Additive effect of endothelial progenitor cell mobilization and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs. J Biomed Sci 2007; 14: 323-330.
38. Sacramento CB, Cantagalli VD, Grings M, et al. Granulocytemacrophage colony-stimulating factor gene based therapy for acute limb ischemia in a mouse model. J Gene Med 2009; 11: 345-353.
39. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966-973.
40. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004; 113: 516-527.
41. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90: 4153-4161.
42. McCourtM, Wang JH, Sookhai S, RedmondHP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134: 1325-1331.
43. WebbNJ, Myers CR, Watson CJ, BottomleyMJ, Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998; 10: 254-257.
44. Ohki Y, Heissig B, Sato Y, et al. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 2005; 19: 2005-2007.
45. TodiscoE, CastagnaL, SarinaB, et al. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Eur J Haematol 2007; 78: 111-116.
46. Ellis SG, Penn MS, Bolwell B, et al. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J 2006; 152: 1051 and 1059-1014.
47. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hema- topoietic stem cells. J Exp Med 2001; 193: 1005-1014.
48. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hema-topoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.